Gossamer Bio股价盘前暴跌80%,其肺部疾病药物未能达到后期试验目标

美股速递
Feb 23

Gossamer Bio Inc. 股价在盘前交易中遭遇断崖式下跌,跌幅高达80%,此前该公司宣布其针对肺部疾病研发的药物在关键后期试验中未能达到主要目标。

这一重大挫折直接源于其核心候选药物的临床试验结果未达预期,导致市场对该公司的前景迅速转向悲观。投资者信心遭受重创,反映出生物科技领域高风险高回报的特性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10